科華生物(002022.SZ):聖湘生物擬以19.5億元受讓公司18.63%的股份
格隆匯5月12日丨科華生物(002022.SZ)公佈,公司於2021年5月12日收到公司第一大股東珠海保聯的通知,獲悉其於2020年5月12日與聖湘生物(688289.SH)簽署了《股份轉讓協議》,珠海保聯以協議轉讓方式將其持有的科華生物9586.3038萬股股份(佔公司總股本的18.63%)轉讓給聖湘生物,股份轉讓價款合計19.5億元。聖湘生物是一家以自主創新基因技術為核心,集診斷試劑和儀器的研發、生產、銷售,以及第三方醫學檢驗服務於一體的體外診斷整體解決方案提供商。聖湘生物資金來源為自有資金或自籌資金。
此次權益變動完成後,珠海保聯不再持有公司股份,聖湘生物成為公司的第一大股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.